Marriott shares jumped after a Q3 beat, record pipeline growth, and higher fees, though the company trimmed its guidance.
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.
Palantir stock dips despite strong Q3 results, upbeat guidance, analyst upgrades, and launch of new AI venture Aither in Dubai.
Palantir generated growth, with customer upselling. Its peers are "still not seeing measurable return from AI," according to BofA Securities.
Molson Coors stock stays steady after missing Q3 earnings estimates, narrowing 2025 outlook, and reporting declining sales and volumes.
Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock.